Previous 10 | Next 10 |
Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic dystrophy type 1 (DM1) candidate; new preclinical data to be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th...
PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicine...
The CFO trading anomaly is well documented to show abnormal returns among the most knowledgeable insiders. Leveraging the SEC Form 4 database shows there has not been a $1 million CFO share purchase in over 40 days and only 3 so far into 2022. "CFOs utilize more (superior) informa...
A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescue s splicing, restore s chloride channel (Clcn1) function, and durably reverse s myotonia in the HSA LR model...
PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines,...
PITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, ...
David Einhorn's 13F stock portfolio value increased from $1.49B to $1.75B this quarter. Greenlight increased Capri Holdings, ODP Group, Livanova, & Victoria’s Secret while reducing Twitter, Concentrix, & EchoStar. They also added Global Payments while dropping AerCap an...
NeuBase Therapeutics press release (NASDAQ:NBSE): FQ1 GAAP EPS of -$0.24. As of December 31, 2021, the Company had cash and cash equivalents of ~$47.3M, compared with ~$52.9M as of September 30, 2021. NeuBase estimates its current cash and cash equivalents are sufficient to fund currently pla...
Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to su...
PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, ...
News, Short Squeeze, Breakout and More Instantly...
NeuBase Therapeutics Inc. Company Name:
NBSE Stock Symbol:
NYSE Market:
NeuBase Therapeutics Inc. Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
Macquarie Group Ltd ADR (MQBKY) is expected to report for Q4 2024 Hormel Foods Corporation (HRL) is expected to report $0.35 for Q2 2024 Howden Joinery Group Plc ADR (HWDJY) is expected to report for Q1 2024 Eiger BioPharmaceuticals Inc. (EIGRQ) is expected to report for Q1 2024 M...